BTG’s (BTG) Neutral Rating Reaffirmed at J P Morgan Chase & Co
Other analysts also recently issued research reports about the stock. Peel Hunt reiterated a hold rating and issued a GBX 680 ($9.15) target price on shares of BTG in a report on Tuesday, November 14th. Numis Securities restated a buy rating and set a GBX 900 ($12.11) price target on shares of BTG in a research report on Wednesday, September 20th. Finally, Deutsche Bank restated a buy rating and set a GBX 775 ($10.43) price target on shares of BTG in a research report on Friday, October 13th. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the company. BTG currently has an average rating of Buy and an average target price of GBX 771.63 ($10.39).
BTG (LON:BTG) opened at GBX 741 ($9.97) on Friday. BTG has a 1-year low of GBX 528.36 ($7.11) and a 1-year high of GBX 779 ($10.48).
BTG (LON:BTG) last released its quarterly earnings data on Tuesday, November 14th. The company reported GBX 21 ($0.28) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of GBX 21 ($0.28). The firm had revenue of £341.30 million for the quarter. BTG had a net margin of 15.50% and a return on equity of 10.80%.
BTG Company Profile
BTG plc is engaged in the business of healthcare, focusing on Interventional Medicine therapies for liver cancer, emphysema and vascular disorders, specialty pharmaceuticals for acute care uses, and a licensing business. The Company operates through three segments: Interventional Medicine, Specialty Pharmaceuticals and Licensing.
Receive News & Ratings for BTG plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BTG plc and related companies with Analyst Ratings Network's FREE daily email newsletter.